Literature DB >> 25073626

Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study.

Paola Muti1, Andrea Sacconi2, Ahmed Hossain3, Sara Donzelli2, Noa Bossel Ben Moshe4, Federica Ganci2, Sabina Sieri5, Vittorio Krogh5, Franco Berrino5, Francesca Biagioni2, Sabrina Strano6, Joseph Beyene3, Yosef Yarden7, Giovanni Blandino8.   

Abstract

BACKGROUND: miRNAs have been implicated in the regulation of key metabolic, inflammatory, and malignant pathways; hence, they might be considered both predictors and players of cancer development.
METHODS: Using a case-control study design nested in the ORDET prospective cohort study, we addressed the possibility that specific mRNAs can serve as early predictors of breast cancer incidence in postmenopausal women. We compared leukocyte miRNA profiles of 133 incident postmenopausal breast cancer cases and profiles of 133 women who remained healthy over a follow-up period of 20 years.
RESULTS: The analysis identified 20 differentially expressed miRNAs, 15 of which were downregulated. Of the 20 miRNAs, miR145-5p and miR145-3p, each derived from another arm of the respective pre-miRNA, were consistently and significantly downregulated in all the databases that we surveyed. For example, analysis of more than 1,500 patients (the UK Metabric cohort) indicated that high abundance of miR145-3p and miR145-5p was associated with longer, and for miR145-3p also statistically significant, survival. The experimental data attributed different roles to the identified miRNAs: Although the 5p isoform was associated with invasion and metastasis, the other isoform seems related to cell proliferation.
CONCLUSIONS: These observations and the prospective design of our study lend support to the hypothesis that downregulation of specific miRNAs constitutes an early event in cancer development. This finding might be used for breast cancer prevention. IMPACT: The identification of the miRNAs as long-term biomarkers of breast cancer may have an impact on breast cancer prevention and early detection. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25073626     DOI: 10.1158/1055-9965.EPI-14-0398

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

1.  What biomarkers (if any) for precise medicine?

Authors:  Sabrina Strano; Paola Muti; Giovanni Blandino
Journal:  Aging (Albany NY)       Date:  2015-08       Impact factor: 5.682

Review 2.  Oncogenic MicroRNAs: Key Players in Malignant Transformation.

Authors:  Tania Frixa; Sara Donzelli; Giovanni Blandino
Journal:  Cancers (Basel)       Date:  2015-12-18       Impact factor: 6.639

3.  Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling.

Authors:  Cenny Taslim; Daniel Y Weng; Theodore M Brasky; Ramona G Dumitrescu; Kun Huang; Bhaskar V S Kallakury; Shiva Krishnan; Adana A Llanos; Catalin Marian; Joseph McElroy; Sallie S Schneider; Scott L Spear; Melissa A Troester; Jo L Freudenheim; Susan Geyer; Peter G Shields
Journal:  Oncotarget       Date:  2016-12-27

4.  circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by regulating the miR-145-5p/CXCL3 axis.

Authors:  Xu Pei; Shi-Wei Chen; Xiang Long; Shu-Qiang Zhu; Bai-Quan Qiu; Kun Lin; Feng Lu; Jian-Jun Xu; Peng-Fei Zhang; Yong-Bing Wu
Journal:  Aging (Albany NY)       Date:  2020-07-02       Impact factor: 5.682

5.  MicroRNAs 145 and 148a Are Upregulated During Congenital Zika Virus Infection.

Authors:  Fernanda L Castro; Victor E V Geddes; Fábio L L Monteiro; Raphael M D T Gonçalves; Loraine Campanati; Paula Pezzuto; Dominic Paquin-Proulx; Bruno L Schamber-Reis; Girlene S Azevedo; Alessandro L Gonçalves; Daniela P Cunha; Maria Elisabeth L Moreira; Zilton F M Vasconcelos; Leila Chimeli; Adriana Melo; Amilcar Tanuri; Douglas F Nixon; Marcelo Ribeiro-Alves; Renato S Aguiar
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

6.  Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Authors:  Sara Donzelli; Federica Mori; Teresa Bellissimo; Andrea Sacconi; Beatrice Casini; Tania Frixa; Giuseppe Roscilli; Luigi Aurisicchio; Francesco Facciolo; Alfredo Pompili; Maria Antonia Carosi; Edoardo Pescarmona; Oreste Segatto; Greg Pond; Paola Muti; Stefano Telera; Sabrina Strano; Yosef Yarden; Giovanni Blandino
Journal:  Oncotarget       Date:  2015-11-03

7.  Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?

Authors:  Mario Cioce; Sabrina Strano; Paola Muti; Giovanni Blandino
Journal:  Aging (Albany NY)       Date:  2016-05       Impact factor: 5.682

8.  Development of a predictive miRNA signature for breast cancer risk among high-risk women.

Authors:  Nicholas H Farina; Jon E Ramsey; Melissa E Cuke; Thomas P Ahern; David J Shirley; Janet L Stein; Gary S Stein; Jane B Lian; Marie E Wood
Journal:  Oncotarget       Date:  2017-11-28

9.  Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Authors:  Silvia Di Agostino; Fabio Valenti; Andrea Sacconi; Giulia Fontemaggi; Matteo Pallocca; Claudio Pulito; Federica Ganci; Paola Muti; Sabrina Strano; Giovanni Blandino
Journal:  Theranostics       Date:  2018-02-12       Impact factor: 11.556

10.  miR-145-5p Inhibits Vascular Smooth Muscle Cells (VSMCs) Proliferation and Migration by Dysregulating the Transforming Growth Factor-b Signaling Cascade.

Authors:  Li Li; Dingbiao Mao; Cheng Li; Ming Li
Journal:  Med Sci Monit       Date:  2018-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.